MX2023010840A - Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados. - Google Patents

Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados.

Info

Publication number
MX2023010840A
MX2023010840A MX2023010840A MX2023010840A MX2023010840A MX 2023010840 A MX2023010840 A MX 2023010840A MX 2023010840 A MX2023010840 A MX 2023010840A MX 2023010840 A MX2023010840 A MX 2023010840A MX 2023010840 A MX2023010840 A MX 2023010840A
Authority
MX
Mexico
Prior art keywords
methods
related compositions
activatable
cytokine
constructs
Prior art date
Application number
MX2023010840A
Other languages
English (en)
Spanish (es)
Inventor
Alexey Yevgenyevich Berezhnoy
Sayantan Mitra
Nicole G Lapuyade
Hikmat Haizar Assi
Madan M Paidhungat
Dylan L Daniel
Walter A Bogdanoff
Na Cai
Scolan Erwan Le
Hsin Wang
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of MX2023010840A publication Critical patent/MX2023010840A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2023010840A 2021-03-16 2022-03-16 Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados. MX2023010840A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163161913P 2021-03-16 2021-03-16
US202163164827P 2021-03-23 2021-03-23
US202163254748P 2021-10-12 2021-10-12
US202163276893P 2021-11-08 2021-11-08
PCT/US2022/020492 WO2022197764A2 (en) 2021-03-16 2022-03-16 Masked activatable cytokine constructs and related compositions and methods

Publications (1)

Publication Number Publication Date
MX2023010840A true MX2023010840A (es) 2023-10-26

Family

ID=81389111

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010840A MX2023010840A (es) 2021-03-16 2022-03-16 Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados.

Country Status (11)

Country Link
US (2) US11667687B2 (https=)
EP (1) EP4308594A2 (https=)
JP (1) JP2024511387A (https=)
KR (1) KR20230157448A (https=)
AU (1) AU2022237504A1 (https=)
BR (1) BR112023018735A2 (https=)
CA (1) CA3211924A1 (https=)
IL (1) IL305716A (https=)
MX (1) MX2023010840A (https=)
TW (1) TW202304958A (https=)
WO (1) WO2022197764A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
JP2024538706A (ja) * 2021-10-08 2024-10-23 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能サイトカイン構成体及び併用方法
WO2024216146A1 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
WO2025066568A1 (zh) * 2023-09-25 2025-04-03 深圳湾实验室 可激活穿膜构建体和降解子
CN121517565A (zh) * 2023-09-25 2026-02-13 深圳湾实验室 可激活穿膜构建体和降解子
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO2001091798A2 (en) 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
DE60129695T2 (de) 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
ATE513563T1 (de) 2000-10-09 2011-07-15 Isis Innovation Therapeutische und toleranz-induzierende antikörper
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US6942853B2 (en) 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
US20060024272A1 (en) 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
MX2007014889A (es) 2005-05-26 2008-02-19 Schering Corp Fusion de interferon-inmunoglobulina g.
JP2009529522A (ja) 2006-03-10 2009-08-20 ディアト 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
WO2009079837A1 (en) 2007-12-18 2009-07-02 Hangzhou Jiuyuan Gene Engineering Co., Ltd. A pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein
US20100189651A1 (en) 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
JP5861223B2 (ja) 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
EP2553101A4 (en) 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
HRP20150664T1 (hr) 2010-12-03 2015-07-31 Adamed Sp. Z O.O. Antikancerogeni fuzijski protein
HRP20200470T1 (hr) 2011-01-18 2020-10-02 Bioniz, Llc Pripravci za modulaciju aktivnosti gama-c-citokina
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
CA2925106C (en) 2013-09-25 2023-11-14 Cytomx Therapeutics, Inc. Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
IL270562B (en) 2014-01-31 2022-08-01 Cytomx Therapeutics Inc Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
GB201411506D0 (en) 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
RS59340B1 (sr) 2014-11-06 2019-10-31 Hoffmann La Roche Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
JP2019518786A (ja) 2016-05-06 2019-07-04 牧林 王 インターロイキンの組み合せ及びその使用
CN110214147A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 IL15/IL15Rα异源二聚体FC-融合蛋白
CN111050803A (zh) * 2017-06-20 2020-04-21 德克萨斯大学系统董事会 用于治疗癌症的干扰素前药
CA3287794A1 (en) 2017-10-14 2025-10-27 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
CA3081539A1 (en) 2017-11-08 2019-05-16 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
CN111954680B (zh) 2017-11-10 2024-03-15 新加坡科技研究局 IL2Rβ/共同γ链抗体
EP3727146A4 (en) 2017-12-19 2021-10-06 Blaze Bioscience, Inc. TUMOR HOMING AND CELL-PENETANT PEPTIDE IMMUNO-ONCOLOGY AGENT COMPLEX AND METHOD OF USE
WO2020113403A1 (en) 2018-12-04 2020-06-11 Beijing Percans Oncology Co. Ltd. Cytokine fusion proteins
WO2019173832A2 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2019230868A1 (ja) 2018-05-30 2019-12-05 中外製薬株式会社 単ドメイン抗体含有リガンド結合分子
US12030721B2 (en) 2018-06-21 2024-07-09 Tgw Logistics Group Gmbh Storage and order picking system and method for picking ordered articles from a hanging bag and another load aid
EP3810624A4 (en) 2018-06-22 2022-07-06 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
CN112867503A (zh) 2018-08-24 2021-05-28 希望之城 掩蔽的细胞因子缀合物
CN120463822A (zh) 2018-09-27 2025-08-12 西里欧发展公司 掩蔽型细胞因子多肽
JP2022502443A (ja) 2018-09-28 2022-01-11 ピエール、ファーブル、メディカマン 癌の処置のための新規な免疫サイトカイン
AU2019366956B2 (en) 2018-10-23 2025-10-30 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
MY205459A (en) 2018-12-06 2024-10-22 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
AU2019395266A1 (en) 2018-12-14 2021-06-17 Proviva Therapeutics (Hong Kong) Limited IL-15 compositions and methods of use thereof
WO2020214690A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
JP2022533254A (ja) 2019-05-24 2022-07-21 プロヴィヴァ セラピューティクス （ホン コン） リミテッド Ｉｌ－２組成物およびその使用方法
CN114127277A (zh) 2019-06-05 2022-03-01 中外制药株式会社 蛋白酶底物和包含蛋白酶切割序列的多肽
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
CA3146156A1 (en) 2019-07-12 2021-01-21 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
MX2022000991A (es) 2019-07-25 2022-05-24 Univ Chicago Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa.
EP4004026A4 (en) 2019-07-25 2023-11-15 Trutino Biosciences Inc. IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER
CA3148505A1 (en) 2019-08-12 2021-02-18 AskGene Pharma, Inc. Novel il-2 fusion molecules
US20220289822A1 (en) 2019-08-21 2022-09-15 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
US20220356221A1 (en) 2019-09-28 2022-11-10 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
CN115315434A (zh) 2019-12-05 2022-11-08 免疫靶向有限公司 白细胞介素15融合蛋白和前药及其组合物和方法
MX2022007202A (es) 2019-12-13 2022-10-07 Cugene Inc Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
US20240043489A1 (en) 2020-01-15 2024-02-08 Trutino Biosciences Inc. Cytokine Prodrugs Comprising a Cleavable Linker
JP7773991B2 (ja) 2020-03-23 2025-11-20 ザイムワークス ビーシー インコーポレイテッド マスクされたｉｌ１２融合タンパク質及びその使用方法
WO2021202354A1 (en) 2020-03-30 2021-10-07 Proviva Therapeutics (Hong Kong) Limited Il-2/il-15 compositions and methods of use thereof
JP7735306B2 (ja) 2020-04-01 2025-09-08 エクシリオ デベロップメント， インコーポレイテッド マスクされたｉｌ－２サイトカイン及びその切断産物
IL296911A (en) 2020-04-01 2022-12-01 Xilio Dev Inc Masked il-15 cytokines and their cleavage products
AU2021248919A1 (en) * 2020-04-01 2022-10-13 Xilio Development, Inc. Masked IL-12 cytokines and their cleavage products
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
US11597753B2 (en) 2020-04-30 2023-03-07 Immune Targeting, Inc. Activatable IL2 composition and methods of use
JP2023526428A (ja) 2020-05-19 2023-06-21 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なｉｌ－１２ポリペプチド及びその使用方法

Also Published As

Publication number Publication date
WO2022197764A2 (en) 2022-09-22
IL305716A (en) 2023-11-01
BR112023018735A2 (pt) 2023-11-28
JP2024511387A (ja) 2024-03-13
US20220306717A1 (en) 2022-09-29
WO2022197764A3 (en) 2022-11-03
CA3211924A1 (en) 2022-09-22
EP4308594A2 (en) 2024-01-24
US11667687B2 (en) 2023-06-06
AU2022237504A1 (en) 2023-10-05
KR20230157448A (ko) 2023-11-16
US20240124546A1 (en) 2024-04-18
TW202304958A (zh) 2023-02-01

Similar Documents

Publication Publication Date Title
MX2022012592A (es) Construcciones de citocinas activables y composiciones y metodos relacionados.
MX2023010840A (es) Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados.
MX2024004301A (es) Construcciones de citocinas activables y metodos combinados.
BR112022022401A2 (pt) Terapia de combinação tripla para aumentar o extermínio de células cancerígenas em cânceres com baixa imunogenicidade
WO2023060156A3 (en) Activatable cytokine constructs and related compositions and methods
GB2378591A (en) RF power amplifier and methods for improving the efficiency thereof
Liu et al. Doxycycline induces Fas/Fas ligand-mediated apoptosis in Jurkat T lymphocytes
CN104702224A (zh) Rf功率放大和分配系统、等离子点火系统及其操作方法
EP4442220A3 (en) Medical device systems and computer-readable mediums for operating the same
WO2022216386A3 (en) T-type calcium channel antagonists and uses thereof
WO2022192439A8 (en) Improving immune cell function
Van de Scheur et al. Pericapillary fibrin cuffs in venous disease: a reappraisal
IL172448A0 (en) Cartesian loop transmitter and method of adjusting an output level of such transmitter
ZA202300222B (en) Anti-αlpha-4-βeta-7 antibodies
CN201113924Y (zh) 带直流偏置的二极管双平衡混频器
GB672865A (en) Improvements in and relating to radio ranging systems
CN201499137U (zh) 功率放大器
AR125090A1 (es) Construcciones de citoquinas activables enmascaradas y composiciones y métodos relacionados
CN202288392U (zh) 解剖型多普勒气囊止血带
CN104836536A (zh) 一种基于负反馈的功率放大器结构
WO2022047353A3 (en) Novel drug-controlled systems and uses thereof
GR950300039T1 (en) Lysozyme dimer and compositions containing the same.
ATE383084T1 (de) Sosse auf käsebasis
AR127274A1 (es) Construcciones de citoquinas activables, y métodos de combinación
CN208608971U (zh) 一种氮化镓微波集成电路脉冲调制电路